Business
Spectral Medical and Vantive Announce Topline Results from Spectral’s Tigris Trial Evaluating PMX Hemoadsorption Therapy for Endotoxic Septic Shock
Results exceed prespecified primary endpoint of 95% posterior probability of benefit for PMX on 28-day mortality Pooled absolute risk reduction of 8.3%; Relative risk reduction of 18% Key secondary endpoint: 90-day Mortality 17.4% lower with PMX and >99% posterior probability of benefit 38.7% Mortality at 28 days with PMX confirms results of prior trial subset TORONTO, Ontario and DEERFIELD, Ill., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral”) (TSX: EDT), a late-stage thera
About this update from Spectral Medical Inc
[{"type":"image","alt":"Spectral Medical Inc.","displaySize":"","headline":null,"caption":"Spectral Medical Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":216,"height":57,"url":"https://media.zenfs.com/en/globenewswire.com/c8dd3eb1a9d6f690331e05a27ac7bc09"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/P6nS4JHS3nYtocpBUIsxfw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c8dd3eb1a9d6f690331e05a27ac7bc09","width":216,"height":57}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Results exceed prespecified primary endpoint of 95% posterior probability of benefit for PMX on 28-day mortality ","length":112,"tagName":"p"}]},{"val":[{"type":"text","content":"Pooled absolute risk reduction of 8.3%; Relative risk reduction of 18% ","length":70,"tagName":"p"}]},{"val":[{"type":"text","content":"Key secondary endpoint: 90-day Mortality 17.4% lower with PMX and >99% posterior probability of benefit ","length":106,"tagName":"p"}]},{"val":[{"type":"text","content":"38.7% Mortality at 28 days with PMX confirms results of prior trial subset ","length":74,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":362,"olType":false},{"type":"text","content":"TORONTO, Ontario and DEERFIELD, Ill., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, and Vantive, a vital organ therapy company committed to pursuing novel diagnostic and therapeutic options for organ failure, today announced topline results from the Tigris trial. This Phase 3 follow-on study sponsored by Spectral evaluated the use of Polymyxin B Hemoadsorption (“PMX”) in a randomized clinical trial of adults treated for endotoxic septic shock.","length":574,"tagName":"p"},{"type":"text","content":"Each year, approximately 5-7 million cases of endotoxic septic shock, a particularly deadly form of sepsis, occur worldwide.1 Today, there is no specific therapy targeting this patient population currently available in the United States. The Tigris trial was a U.S.-based, multicenter, randomized, controlled Phase 3 study evaluating PMX in adults with endotoxic septic shock, defined by an Endotoxin Activity Assay (“EAA”) level between 0.60 and 0.90. EAA is an FDA approved, semiquantitati...